← All trials
NCT05136170
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Jul 31, 2022
- Completion date
- Jan 31, 2023
- First posted
- Nov 29, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dompe PharmaceuticalsLead sponsor
- Dompe PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.